<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03358290</url>
  </required_header>
  <id_info>
    <org_study_id>AE051-G-16-007</org_study_id>
    <nct_id>NCT03358290</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis</brief_title>
  <acronym>CLEAR-PS</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of JTE-051 Administered for 12 Weeks in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR-PS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akros Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akros Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-051
      administered for 12 weeks in subjects with moderate to severe plaque psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving a minimum 75% improvement from baseline in the PASI (psoriasis area and severity index) by Week 12.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Psoriasis area and severity index combines extent of body-surface involvement assessments in 4 anatomical regions and severity of regional desquamation, erythema and plaque induration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in PASI score and proportions of subjects achieving 50% improvement from baseline (PASI 50), 75% improvement from baseline (PASI 75), 90% improvement from baseline (PASI 90) and 100% improvement from baseline (PASI 100).</measure>
    <time_frame>Weeks 2, 4, 8, 12 and 16</time_frame>
    <description>Psoriasis area and severity index combines body-surface assessments and severity of desquamation, erythema and plaque induration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a Static Physician's Global Assessment (sPGA) score of 0 or 1 and change in sPGA score at Weeks 2, 4, 8, 12 and 16 from baseline.</measure>
    <time_frame>Weeks 2, 4, 8, 12 and 16</time_frame>
    <description>The Static Physician's Global Assessment (sPGA) score (0 [clear] to 5 [severe]) is used to determine the severity of subject's psoriatic lesion graded for induration, erythema and scaling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Skindex 16</measure>
    <time_frame>Weeks 2, 4, 8, 12 and 16</time_frame>
    <description>Skindex 16 is a 16-item, skin-related quality of life questionnaire based on 3 domains: symptoms, emotions and functioning. Skindex is measured on a linear scale of 100 from 0 (no effect) to 100 (effect experienced all the time).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events [safety and tolerability]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of treatment-emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic</measure>
    <time_frame>Weeks 2, 4, 8 and 12</time_frame>
    <description>Trough plasma levels of JTE-051</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Plaque Psoriasis</condition>
  <condition>Skin Diseases</condition>
  <arm_group>
    <arm_group_label>JTE-051 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JTE-051 dose 1 for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JTE-051 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JTE-051 dose 2 for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JTE-051 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JTE-051 dose 3 for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JTE-051 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JTE-051 dose 4 for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JTE-051</intervention_name>
    <description>Active drug tablets containing JTE-051</description>
    <arm_group_label>JTE-051 Dose 1</arm_group_label>
    <arm_group_label>JTE-051 Dose 2</arm_group_label>
    <arm_group_label>JTE-051 Dose 3</arm_group_label>
    <arm_group_label>JTE-051 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets identical in appearance to the active drug tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with moderate to severe plaque psoriasis at least 6 months prior to Visit 1

          -  Plaque-type psoriasis covering ≥10% of body surface area (BSA) at Visit 1 and Visit 2;

          -  Psoriasis Area and Severity Index (PASI) score ≥12 at Visit 1 and Visit 2;

          -  Static Physician's Global Assessment (sPGA) score ≥3 at Visit 1 and Visit 2;

          -  Body Mass Index (BMI) ≤38 at Visit 1.

        Exclusion Criteria:

          -  Medical history of treatment failure to any systemic agents for plaque psoriasis;

          -  Prior exposure to more than one biologic agent treatment;

          -  Presence of erythrodermic psoriasis, pustular psoriasis, guttate psoriasis,
             medication-induced psoriasis or other skin conditions at (e.g., clinically-significant
             eczema or severe acne) that could interfere with study evaluations at Visit 1;

          -  Presence or history of any itch due to underlying conditions other than plaque
             psoriasis which cause or influence pruritus of the skin (e.g., drug induced pruritus,
             significant other systemic diseases with itch) within 12 months prior to Visit 1;

          -  History of a clinically-significant infection (e.g., that required oral antimicrobial
             therapy) within 8 weeks prior to Visit 2;

          -  History of infections requiring hospitalization or parenteral antibiotic, antiviral,
             antifungal or antiparasitic therapy within 6 months prior to Visit 2 and no history of
             recurrent infections or conditions predisposing to chronic infections (e.g.,
             bronchiectasis, chronic osteomyelitis);

          -  History of or at risk for destructive arthropathy (e.g., rapidly progressing
             osteoarthritis, osteonecrosis, spontaneous osteonecrosis of the knee, subchondral
             insufficiency fracture, hip dislocation and pathologic fracture) at Visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yoshiro Masuda</last_name>
    <phone>609-919-9570</phone>
    <email>ClinicalTrials@akrospharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First OC Dermatology</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center For Dermatology Clinical Research, Inc.</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of South Florida - Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlanta Dermatology Vein and Research Center LLC</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research, PC</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research - Dermatology Center of Canyon County</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>83651</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansas City Dermatology P.A.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215-2309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Forest Hills Dermatology Group</name>
      <address>
        <city>Forest Hills</city>
        <state>New York</state>
        <zip>11375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of the Carolinas</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Treatment and Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karma Clinical Trials</name>
      <address>
        <city>Saint John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 4Y3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mediprobe Research Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5X 2P1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>David Gratton's Private Practice</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>JTE-051</keyword>
  <keyword>Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

